Pituitary disorders:

Indications for: Cabergoline

Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors.

Adult Dosage:

Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly.

Children Dosage:

Not established.

Cabergoline Contraindications:

Uncontrolled hypertension. Sensitivity to ergot alkaloids.

Cabergoline Warnings/Precautions:

Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Psychiatric disorders (eg, impulse control/compulsive behaviors, pathological gambling, increased libido). Hepatic impairment. Pregnancy. Nursing mothers: not recommended.

Cabergoline Classification:

Dopamine agonist.

Cabergoline Interactions:

Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives.

Adverse Reactions:

GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy.


Formerly known under the brand name Dostinex.

How Supplied:

Contact supplier.